T2 BIOSYSTEMS INC (TTOO)

US89853L3024 - Common Stock

0.425  +0.02 (+3.66%)

Premarket: 0.47 +0.04 (+10.59%)

Fundamental Rating

1

TTOO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. TTOO may be in some trouble as it scores bad on both profitability and health. TTOO is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

In the past year TTOO has reported negative net income.
In the past year TTOO has reported a negative cash flow from operations.
In the past 5 years TTOO always reported negative net income.
TTOO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -237.55%, TTOO is doing worse than 92.51% of the companies in the same industry.
Industry RankSector Rank
ROA -237.55%
ROE N/A
ROIC N/A
ROA(3y)-135.6%
ROA(5y)-134.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TTOO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

TTOO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TTOO has more shares outstanding
Compared to 5 years ago, TTOO has more shares outstanding
The debt/assets ratio for TTOO has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -55.73, we must say that TTOO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -55.73, TTOO is not doing good in the industry: 95.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -55.73
ROIC/WACCN/A
WACC8.27%

2.3 Liquidity

TTOO has a Current Ratio of 0.40. This is a bad value and indicates that TTOO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.40, TTOO is not doing good in the industry: 94.65% of the companies in the same industry are doing better.
A Quick Ratio of 0.24 indicates that TTOO may have some problems paying its short term obligations.
TTOO has a worse Quick ratio (0.24) than 95.90% of its industry peers.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.24

4

3. Growth

3.1 Past

TTOO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.25%, which is quite impressive.
Looking at the last year, TTOO shows a very negative growth in Revenue. The Revenue has decreased by -30.16% in the last year.
Measured over the past years, TTOO shows a decrease in Revenue. The Revenue has been decreasing by -7.29% on average per year.
EPS 1Y (TTM)97.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.59%
Revenue 1Y (TTM)-30.16%
Revenue growth 3Y-26.52%
Revenue growth 5Y-7.29%
Sales Q2Q%34.85%

3.2 Future

TTOO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.64% yearly.
The Revenue is expected to grow by 54.19% on average over the next years. This is a very strong growth
EPS Next Y83.26%
EPS Next 2Y39.13%
EPS Next 3Y25.19%
EPS Next 5Y14.64%
Revenue Next Year51.43%
Revenue Next 2Y81.66%
Revenue Next 3Y68.18%
Revenue Next 5Y54.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TTOO. In the last year negative earnings were reported.
Also next year TTOO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

TTOO's earnings are expected to grow with 25.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.13%
EPS Next 3Y25.19%

0

5. Dividend

5.1 Amount

TTOO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

T2 BIOSYSTEMS INC

NASDAQ:TTOO (12/27/2024, 8:00:01 PM)

Premarket: 0.47 +0.04 (+10.59%)

0.425

+0.02 (+3.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-13 2025-02-13/amc
Inst Owners13.56%
Inst Owner Change-8.46%
Ins Owners0.12%
Ins Owner Change0%
Market Cap8.94M
Analysts43.33
Price Target5.1 (1100%)
Short Float %10.19%
Short Ratio0.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.68%
Min Revenue beat(2)-30.5%
Max Revenue beat(2)-8.87%
Revenue beat(4)1
Avg Revenue beat(4)-7.69%
Min Revenue beat(4)-30.5%
Max Revenue beat(4)26.29%
Revenue beat(8)1
Avg Revenue beat(8)-6.63%
Revenue beat(12)3
Avg Revenue beat(12)-6.67%
Revenue beat(16)6
Avg Revenue beat(16)-2.71%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.16
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.82
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.74
OCFYN/A
SpS0.36
BVpS-0.56
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -237.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-135.6%
ROA(5y)-134.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.24
Altman-Z -55.73
F-Score3
WACC8.27%
ROIC/WACCN/A
Cap/Depr(3y)30.32%
Cap/Depr(5y)34.46%
Cap/Sales(3y)1.94%
Cap/Sales(5y)3.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.59%
EPS Next Y83.26%
EPS Next 2Y39.13%
EPS Next 3Y25.19%
EPS Next 5Y14.64%
Revenue 1Y (TTM)-30.16%
Revenue growth 3Y-26.52%
Revenue growth 5Y-7.29%
Sales Q2Q%34.85%
Revenue Next Year51.43%
Revenue Next 2Y81.66%
Revenue Next 3Y68.18%
Revenue Next 5Y54.19%
EBIT growth 1Y12.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.02%
OCF growth 3YN/A
OCF growth 5YN/A